Hopman Mark 4/A

What Happened
Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), received a derivative award on February 27, 2026 covering 91,520 shares. The reported transaction shows $0 paid for the award (a grant/award rather than an open‑market purchase or sale). This Form 4 is an amendment to correct the number of shares reported in the original filing.

Key Details

• Transaction date: 2026-02-27 (original Form 4 filed 2026-03-03; this amended Form 4 filed 2026-03-13 to correct share count).
• Transaction type/code: Award/Grant (A), derivative award reported at $0.00 per share for 91,520 shares.
• Vesting: Footnote indicates shares vest in 36 equal monthly installments starting March 1, 2026.
• Shares owned after transaction: Not specified in the information provided on this filing.
• Timeliness: Original Form 4 was filed on Mar 3, 2026 (timely within reporting window); this filing is an amendment to correct the previously reported share count.

Context
This is a grant/award of a derivative security (likely stock options or restricted units) rather than an immediate purchase or sale. Vesting over 36 months means the award becomes exercisable/vested gradually; there is no indication here that any shares were sold or exercised immediately. Amendments like this are routine when correcting reporting details; they do not by themselves indicate a change in insider intent.